Anastrozole, marketed under the pharmaceutical brand name Arimidex, is a third generation non steroidal aromatase inhibitor with FDA approval for breast cancer treatment and one of the most extensively documented clinical histories of any estrogen management compound. This generic brand formulation delivers 1mg per tablet in a 30 count format. A lower tablet count than CSD’s Axon Pharma Corp Anastrozole 1mg 45 tablet listing at identical compound and concentration, providing a shorter supply duration suited to research protocols requiring a single defined 30 day aromatase inhibition period or researchers evaluating Anastrozole compound performance before committing to the higher tablet count presentation.
The 30 tablet format serves a distinct procurement purpose from the 45 tablet Axon Pharma Corp presentation. For research protocols specifically designed around a 30 day aromatase inhibition observation window, a common research design timepoint in comparative AI and hormonal modulation studies. The 30 tablet supply provides a precisely matched compound volume without excess tablet supply beyond the protocol’s defined endpoint. For researchers initiating Anastrozole protocols or conducting shorter duration comparative AI studies, the reduced tablet count minimizes initial compound commitment while providing sufficient supply for a complete 30 day research cycle at once daily administration.
Anastrozole’s core pharmacological profile remains consistent across both CSD presentations; competitive reversible CYP19A1 aromatase enzyme inhibition reducing systemic estrogen production without affecting adrenal corticosteroid or aldosterone synthesis, documented aromatase suppression of approximately 96 to 97% at the 1mg dose, and a well characterized pharmacokinetic profile with approximately 50 hour half-life supporting once daily administration in research protocols. The generic brand sourcing and 30 tablet format represent the sole differentiating variables from the Axon Pharma Corp listing; base compound, concentration, mechanism, and pharmacological activity remaining identical across both presentations.
Every batch of CSD’s Anastrozole is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our aromatase inhibitor range. Anastrozole across two presentations, Letrozole, and Exemestane across two presentations: covers all three mechanistically distinct AI approaches from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Letrozole and Exemestane in comparative aromatase inhibitor potency and estrogen suppression studies. Browse CSD’s full PCT and hormone research range for complete sourcing.
![ESTRADIOL 2MG X 100 [HORMONE THERAPY]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/10/ESTRADIOL-2-X-100-300x300.webp)
